Cargando…
CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner
Combining immunotherapy with targeted therapy has increasingly become an appealing therapeutic paradigm for cancer treatment due to its great potential for generating durable and synergistic antitumor response. In this study, however, we unexpectedly found that two types of CpG-based tumor peptide v...
Autores principales: | Huang, L, Wang, Z, Liu, C, Xu, C, Mbofung, R M, McKenzie, J A, Khong, H, Hwu, P, Peng, W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5509483/ https://www.ncbi.nlm.nih.gov/pubmed/28263973 http://dx.doi.org/10.1038/onc.2017.35 |
Ejemplares similares
-
CpG-Based Nanovaccines for Cancer Immunotherapy
por: Chen, Wenqiang, et al.
Publicado: (2021) -
Antibody targeted CpG for the immunotherapy of solid tumors
por: Epstein, Alan L, et al.
Publicado: (2015) -
The revival of CpG oligonucleotide-based cancer immunotherapies
por: Adamus, Tomasz, et al.
Publicado: (2018) -
Preservation of methylated CpG dinucleotides in human CpG islands
por: Panchin, Alexander Y., et al.
Publicado: (2016) -
Suppressive CpG
por: Van Epps, Heather L.
Publicado: (2005)